Christie Bielinski

Offering an overview of how breakthrough therapy designations have historically worked and how that process is changing Are we as an industry ready for major changes in how drug development is expedited? Discussing how our organizations’ Quality Culture must be an integral part at all stages of this transition Working with all stakeholders to ensure we do not sacrifice safety and quality as we increase the pace of innovation What should we be doing right now to prepare for the future of these developments? — Christie Bielinski, Vice President of Product Quality Management at Janssen Pharmaceuticals, leads a world-wide organization of quality professionals…